School of Psychology, University of New South Wales, Sydney, New South Wales, Australia.
Appl Psychol Health Well Being. 2023 Nov;15(4):1406-1426. doi: 10.1111/aphw.12444. Epub 2023 Mar 18.
Open label placebos (OLPs) appear generally efficacious among clinical samples, but the empirical evidence regarding their use in non-clinical and sub-clinical samples, as well as when administered independent of a convincing rationale, is mixed. Healthy participants (N = 102) were randomised to either a 6-day course of OLP pills with information provision (OLP-plus: N = 35), without information provision (OLP-only: N = 35), or no-treatment control group (N = 32). OLP pills were described as enhancing physical (symptoms and sleep) and psychological (positive and negative emotional) well-being. Well-being was assessed at baseline and on Day 6. Expectancies and adherence were measured. OLP administration interacted with baseline well-being. The OLP-plus group demonstrated increased well-being on all outcomes other than positive emotions, but only when they reported decreased baseline well-being. OLP-only and control groups did not differ. The OLP-plus group demonstrated elevated expectancies, that mediated the OLP effect on physical symptoms relative to control, but only when well-being was lower than average at baseline (i.e. moderated-mediation). Results demonstrate the importance of information provided with OLPs. The moderating effect of baseline outcomes may reconcile inconsistent results regarding clinical and non-clinical samples. Accounting for baseline symptoms in non-clinical and sub-clinical samples is likely to enhance our understanding of when OLPs are effective.
开放性安慰剂(OLP)在临床样本中通常表现出疗效,但关于其在非临床和亚临床样本中的使用,以及在没有令人信服的理由的情况下独立使用时的经验证据是混杂的。102 名健康参与者被随机分配到为期 6 天的 OLP 药丸加信息提供组(OLP-plus:N=35)、无信息提供 OLP 仅组(OLP-only:N=35)或无治疗对照组(N=32)。OLP 药丸被描述为增强身体(症状和睡眠)和心理(积极和消极情绪)健康。在基线和第 6 天评估健康状况。测量了预期和依从性。OLP 给药与基线健康状况相互作用。OLP-plus 组在除积极情绪外的所有结果上都表现出健康状况的改善,但前提是他们报告的基线健康状况下降。OLP-only 和对照组没有差异。OLP-plus 组表现出更高的预期,这在控制组的基础上中介了 OLP 对身体症状的影响,但前提是基线健康状况低于平均水平(即调节中介)。结果表明了与 OLP 一起提供信息的重要性。基线结果的调节作用可能调和了关于临床和非临床样本的不一致结果。在非临床和亚临床样本中考虑基线症状可能会增强我们对 OLP 何时有效的理解。